A Phase 1, First-in-human Study of JNJ-80948543, a T-cell Redirecting Antibody, in Participants with NHL and CLL

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-504187-42-00

Acronym

80948543LYM1001

Enrollment

Registered

2023-07-12

Start date

2022-09-12

Completion date

Unknown

Last updated

2025-11-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

None listed

Sex/Gender

All

Age

18 Years to No maximum

Denmark, France, Poland

None listed

Source: EU CTIS · Data processed: Feb 4, 2026